tbuckley/cabot-search huggingface dataset:
Abstract 3645: Cooperation between canonical Wnt and TGF-beta pathways promotes sarcoma angiogenesis
Authors: Allegra G. Hawkins, Elisabeth A. Pedersen, Wei Jiang, Sydney Treichel, Colin Sperring, Jay Read, Brian Magnuson, Rajiv M. Patel, Dafydd Thomas, Rashmi Chugh, Elizabeth R. Lawlor
Journal: Cancer Research (2019)

Abstract Local and metastatic progression of solid tumors depends on crosstalk between tumor cells and the tumor microenvironment (TME), including both stromal cells and the extracellular matrix (ECM). We recently showed that high Wnt/beta-catenin activity in Ewing sarcoma correlates with diminished patient survival and that canonical Wnt signaling alters the tumor secretome, influencing ECM protein composition. In light of this, we investigated the hypothesis that Wnt/beta-catenin supports tumor progression by modulating tumor: TME crosstalk. Our results reveal that, in discrete tumor cell sub-populations, beta-catenin activation sensitizes cells to TGF-beta ligands through derepression of the TGF-beta receptor, TGFBR2, resulting in canonical Wnt-induced, TGF-beta-dependent upregulation of TGF-beta targets. Significantly, these Wnt/TGF-beta responsive targets include multiple AngioMatrix genes that are known to alter the TME to promote angiogenesis, including tenascin-C and collagens. Studies of Ewing sarcoma models, in vitro and in vivo, as well as in two independent patient cohorts, confirm that a direct relationship exists between beta-catenin and TGF-beta activation in tumor cells and angiogenesis in the local TME. Mechanistically, this is due, in part, to tenascin C-mediated promotion of endothelial cell proliferation. Thus, functional cooperation between canonical Wnt and TGF-beta signaling in Ewing cells induces secretion of pro-angiogenic factors. This study reveals a novel link between Wnt and TGF-beta signaling in Ewing sarcoma and illustrates the critical contribution of tumor cell heterogeneity and tumor: TME crosstalk to sarcoma progression. Citation Format: Allegra G. Hawkins, Elisabeth A. Pedersen, Wei Jiang, Sydney Treichel, Colin Sperring, Jay Read, Brian Magnuson, Rajiv M. Patel, Dafydd Thomas, Rashmi Chugh, Elizabeth R. Lawlor. Cooperation between canonical Wnt and TGF-beta pathways promotes sarcoma angiogenesis [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 3645.
Toxic shock and tampons.
Journal: BMJ (1980)

Toxic shock and tamponsReports from the United States of a new, sometimes fatal illness associated with the use of tampons have surprised British gynaecologists and pathologists.The new syndrome is, in fact, an addition to the already wide range of diseases produced by Staphylococcus aureus.Ogston's coccus is a remarkably versatile organism, and it seems curiously fitting that 100 years 'after the first description of its pathogenic role in abscesses it should present a new diagnostic challenge.Two years ago Todd et all described an acute severe illness
PTH-106 Bile Acid Diarrhoea Masquerades As Diarrhoea-predominant Irritable Bowel Syndrome: Results From A Dual Centre Prospective Study
Authors: I Aziz, S Mumtaz, H Bholah, FU Chowdhury, DS Sanders, AC Ford
Journal: Gut (2014)

<h3>Introduction</h3> Several studies have suggested that bile acid diarrhoea (BAD) can present with symptoms that are compatible with diarrhoea-predominant irritable bowel syndrome (IBS-D). However, uncertainty exists as these have often been retrospective, have not defined IBS-D according to accepted diagnostic criteria, or have included patients with chronic diarrhoea in the analysis. We have examined this issue in a well-characterised cohort of patients with rigorously defined IBS-D. <h3>Methods</h3> This was a prospective cross-sectional survey conducted among consecutive patients with IBS-D attending Gastroenterology clinics in two hospitals in Sheffield and Leeds, UK. All patients underwent 23-seleno-25-homo-tauro-cholic acid (SeHCAT) scanning according to local protocol, with a retention of &lt;15% at day 7 used to confirm BAD. The degree of BAD was classed as severe if retention &lt; 5%, moderate if 5.0 &gt;9.9%, and mild if 10.0 &gt;14.9%. Presence of IBS-D was defined according to the Rome III criteria. Patients with other known risk factors for BAD, including previous cholecystectomy, terminal ileal Crohn’s disease, terminal ileal resection, pelvic or abdominal radiotherapy, coeliac disease, or microscopic colitis, were excluded. Participants completed the patient health questionnaire-15, a validated somatisation score, and the hospital anxiety and depression score. Demographic data, including age, gender, lifestyle, and body mass index (BMI) were collected. The effect of all these factors on presence or absence of BAD was examined by multivariate logistic regression analysis, with results expressed as odds ratios (ORs) with 99% confidence intervals. <h3>Results</h3> This is an interim analysis of an ongoing study. In total, 51 patients with IBS-D according to the Rome III criteria have been recruited to date (37 (72.5%) female, mean age 47.0 years). In total, 14 (27.5%) were found to have BAD following SeHCAT scanning. Of these, nine (17.6%) had severe BAD, four moderate, and one mild. Mean age, BMI, anxiety, depression, and somatisation scores were not significantly different among those with, compared with those without, BAD. No predictors of presence of BAD were identified following multivariate logistic regression. <h3>Conclusion</h3> Our data suggest that more than one-in-four IBS-D patients, if investigated, have definite evidence of BAD. In the majority, this is severe. Failure to investigate patients to exclude BAD as an underlying cause of symptoms compatible with IBS-D results in misdiagnosis and a failure to institute effective therapy, in the form of bile acid sequestrants. This suggests that future IBS management guidelines should advocate diagnostic testing to exclude BAD before a diagnosis of IBS-D is made. <h3>Disclosure of Interest</h3> None Declared.
Where Credit Is Due
Journal: JAMA (1965)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
From the Agency for Health Care Policy and Research
Authors: J. Jarrett Clinton
Journal: JAMA (1990)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Byline Omitted
Journal: JAMA (1987)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
580. Gene Therapy of Chronic Hepatitis B Infection Using a High-Capacity Adenovirus Expressing Interleukin 12 under the Control of a Liver Specific Mifepristone-Inducible Promoter
Authors: Julien S. Crettaz, Pedro Berraondo, Laura Ochoa, Astrid Paneda, Itziar Otano, Cristina Olague, Africa Vales, Stefan Kochanek, Jesus Prieto, Gloria Gonzalez-Aseguinolaza
Journal: Molecular Therapy (2006)

Three hundred fifty millions people are estimated to be infected by the hepatitis B virus (HBV). Eighty-seven millions of them would develop HBV-related liver cancer or cirrhosis. In this study we developed a high-capacity adenovirus (HC-Ad), characterized by its low toxicity and long-term expression, encoding for the murine interleukin 12 (mIL12) directed by a liver-specific promoter and inducible by the administration of mifepristone (HC-RU-mIL12). We assayed its antiviral effect using two animal models of chronic HBV infection: transgenic mice for the HBV genome and woodchucks chronically infected by the woodchuck hepatitis virus (WHV). HBV transgenic mice received 2x10e8 infective units (iu) of HC- RU-mIL12. Two weeks later they received five daily doses of inductor (mifepristone). Treated animals showed a complete abrogation of serum viral load and the concentration of viral antigens (HBsAg y HBeAg) decreased significantly, whereas the viremia of control groups remained stable. Two woodchucks (w173 and w762) received 9x10e9 iu of HC- RU-mIL12. A third one (w752) received only inductor and was used as control. Woodchucks were treated daily during eleven days with 500 μg of mifepristone per kg of body-weight. Woodchuck w762 expressed low levels of mIL12 and its viremia remained unchanged during the whole treatment period. However woodchuck w173 expressed high levels of mIL12 in peripheral blood and suffered a spectacular decrease of its viremia higher than 6 logarithms. At the end of the treatment, the viremia of this animal remained constant during more than one year, below our detection limit. In both treated woodchucks the recombinant virus induced a significant activation of cellular immune response against core antigen (WHcAg). No changes were observed in control woodchuck. No toxicity was detected due to the virus or IL12. These experiments demonstrate the antiviral efficacy of our treatment using HC-Ad expressing mIL12 in HBV transgenic mice and more importantly in WHV chronically infected woodchucks. Furthermore, we were able to induce a strong antigen-specific immune response in this animal model. We validate the HC-RU-mIL12 as a safe and innocuous vector, probably due to the localized and controlled expression of the cytokine. Studies with a larger number of animals are being conducted.
COLOMBIA
Journal: JAMA (1953)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
PDF Cells Are a GABA-Responsive Wake-Promoting Component of the Drosophila Sleep Circuit
Authors: Katherine M. Parisky, Jose Agosto, Stefan R. Pulver, Yuhua Shang, Elena Kuklin, James J.L. Hodge, Kyeongjin Kang, Xu Liu, Paul A. Garrity, Michael Rosbash, Leslie C. Griffith
Journal: Neuron (2009)
Medical News
Journal: JAMA (1973)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Cooling then culling blood complexes combats arthritis
Authors: H. Page
Journal: JAMA (1982)

Apheresis to treat patients with rheumatoid arthritis continues to intrigue investigators, although the procedure is considered experimental and the subset of patients who may benefit needs to be identified. In one trial reported at the Pan-American Congress of Rheumatology in Washington, DC, a variation called cryopheresis that is used to remove circulating immune complexes achieved "significant improvement in clinical parameters" in 14 of 16 patients whose conditions previously had failed to improve on at least one major therapeutic regimen. The study was conducted by Randall Krakauer, MD, of the Cleveland Clinic Foundation, and associates in other cities. The technique, Krakauer explained, takes advantage of the cryoprecipitability of some immune complexes: when plasma is separated from other blood elements with a hollow filter and cooled to 0.7°C, immune complexes come out of solution and can be removed by centrifugation or filtration. The remainder of the plasma is reheated and returned to
Oral metronomic therapy in head and neck cancer
Authors: Raja Pramanik, Atul Sharma, Akash Kumar
Journal: The Lancet Global Health (2020)

We congratulate Vijay Patil and colleagues (September, 2020)1 for providing level 1 evidence of the upfront use of oral metronomic chemotherapy for head and neck squamous cell carcinoma, which is a huge burden in low-income and middle-income countries (LMICs), where affording immuno-oncology drugs and EGFR-targeted agents is out of the question. This study is extremely relevant during the current pandemic, allowing oral therapy at home. Although the study appears practice-changing, certain issues should be put into perspective.
Inhibition of viral replication by genetically engineered mutants of the duck hepatitis B virus core protein
Authors: F VONWEIZSACKER
Journal: Hepatology (1996)

The hepatitis B virus (HBV) nucleocapsid consists of 240 viral core proteins that are arranged in a highly symmetrical structure, HBV replication can only take place inside intact nucleocapsids. In the present study, we investigated whether genetically engineered core mutants can inhibit viral replication by interfering with the formation of intact nucleocapsids. Using the duck hepatitis B virus (DHBV) model, a series of core protein mutants was generated. Polymerase chain reaction-amplified fragments from the bacterial lacZ gene expressing up to 282 amino acids were added either to the amino- or carboxy-terminus of the DHBV core protein. In addition, carboxy-terminal extensions were generated by fusing the DHBV core protein with the DHBV small surface protein or various fragments of the viral polymerase. Finally, the green fluorescent protein (GFP) was fused in-frame to the carboxy-terminus of the DHBV core protein. In this chimeric protein, GFP is still functional and can act as a reporter molecule. The various core protein mutants were tested for their potential antiviral activity by cotransfection with a replication-competent DHBV construct into the avian hepatoma cell line LMH. Carboxy-terminal, but not amino-terminal, DHBV core mutants inhibited DHBV replication by up to 90% at an effector-to-target ratio of 1:10, thus displaying a dominant negative phenotype. Antiviral activity was species-specific and caused by posttranslational interference with viral replication. The DHBV core-GFP fusion protein should be an ideal tool to assess the antiviral potential of dominant negative core proteins in vivo. (Hepatology 1996 Aug;24(2):294-9)
Incidence, Predictors and Outcomes of Acute on Chronic Liver Failure in Outpatients with Cirrhosis
Authors: S. Piano, M. Tonon, C. Pilutti, E. Vettore, M.L. Stanco, F. Morando, S. Rosi, A. Romano, E. Gola, A. Sticca, S. Fasolato, P. Angeli
Journal: Journal of Hepatology (2016)
Investigation of a New Diagnosis of Multidrug-Resistant, Dual-Tropic HIV-1 Infection—New York City, 2005
Journal: JAMA (2006)

INFECTION WITH A strain of multidrug-resistant (MDR), dual-tropic* human immunodeficiency virus (HIV)-1 was newly diagnosed in a man aged 46 years in New York City (NYC).The man (i.e., the index patient) had no history of antiretroviral treatment and reported having sex with multiple named and anonymous male partners, using crystal methamphetamine, and engaging in unprotected insertive and receptive anal intercourse.He had rapid progression to acquired immunodeficiency syndrome (AIDS) after experiencing signs and symptoms of acute HIV infection.The case was reported to the New York City Department of Health and Mental Hygiene (NYCDOH) in late January 2005 and has been described previously. 1 This report describes the public health investigation of the index patient's reported contacts and a review of viral genetic sequencing (genotype) results from other HIV-infected patients in the NYC region to estimate the prevalence of this strain of HIV.The investigation, conducted by NYCDOH, Connecticut Department of Public H e a l t h , A a r o n D i a m o n d A I D S Research Center, New York State Department of Health, and CDC, identified three other patients with similar risk factors who engaged in high-risk sexual activity at the same time and in the same venues as the
Freshman Hygiene: Personal and Social Problems of the College Student.
Journal: JAMA (1926)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Omission of Tables
Journal: JAMA (1982)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal